Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$6.22 USD
-0.30 (-4.60%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $6.23 +0.01 (0.16%) 7:58 PM ET
5-Strong Sell of 5 5
C Value B Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IRWD 6.22 -0.30(-4.60%)
Will IRWD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IRWD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRWD
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline
IRWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
Other News for IRWD
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Ironwood Pharma Elevates CFO and Repays Convertible Notes
Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD)
Insider Sale: Director Catherine Moukheibir Sells 80,000 Shares of Ironwood Pharmaceuticals Inc ...